Barely Significant
← all excerpts

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.

Mol Cancer Ther · 2025 · PMC12402799 · PMID 40300249

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)
The changes in p-S6 and p-mTOR with treatment were not statistically significant upon IHC, but pS6 showed a trend toward an increase in p-S6 ( P = 0.06; Supplementary Fig. 9).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.